MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
1.060
-0.020
-1.85%
After Hours: 1.050 -0.01 -0.94% 19:58 05/08 EDT
OPEN
1.070
PREV CLOSE
1.080
HIGH
1.090
LOW
1.010
VOLUME
5.59M
TURNOVER
--
52 WEEK HIGH
2.930
52 WEEK LOW
0.5469
MARKET CAP
235.34M
P/E (TTM)
-4.1053
1D
5D
1M
3M
1Y
5Y
1D
Humacyte Receives Nasdaq Notice on Minimum Bid Requirement
TipRanks · 22h ago
Humacyte risks Nasdaq delisting after shares trade below $1 bid price minimum
PUBT · 23h ago
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
Barchart · 1d ago
Humacyte sets first-quarter results webcast and conference call
PUBT · 1d ago
HUMACYTE TO ANNOUNCE 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 13, 2026
Reuters · 1d ago
Humacyte (HUMA) Motion to Dismiss Ruling Keeps Key Securities Claims Alive 
TipRanks · 5d ago
Weekly Report: what happened at HUMA last week (0427-0501)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Beam Therapeutics (BEAM) and Humacyte (HUMA)
TipRanks · 04/29 10:30
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.